4.7 Article

OPENchip: an on-chip in situ molecular profiling platform for gene expression analysis and oncogenic mutation detection in single circulating tumour cells

Journal

LAB ON A CHIP
Volume 20, Issue 5, Pages 912-922

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c9lc01248f

Keywords

-

Funding

  1. Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT AMP
  2. Future Planning [2015K1A4A3047345]
  3. Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2019R1I1A1A01059219]
  4. Brain Korea 21 Plus Project in 2018
  5. Swedish Research Council (Vetenskapsradet)
  6. Swedish Cancer Foundation (Cancerfonden)
  7. strategic research area UCAN
  8. European Union [764281]
  9. Brain Korea 21 Plus Project in 2019
  10. Brain Korea 21 Plus Project in 2020
  11. Marie Curie Actions (MSCA) [764281] Funding Source: Marie Curie Actions (MSCA)
  12. National Research Foundation of Korea [2019R1I1A1A01059219] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Liquid biopsy holds promise towards practical implementation of personalized theranostics of cancer. In particular, circulating tumour cells (CTCs) can provide clinically actionable information that can be directly linked to prognosis or therapy decisions. In this study, gene expression patterns and genetic mutations in single CTCs are simultaneously analysed by strategically combining microfluidic technology and in situ molecular profiling technique. Towards this, the development and demonstration of the OPENchip (On-chip Post-processing ENabling chip) platform for single CTC analysis by epithelial CTC enrichment and subsequent in situ molecular profiling is reported. For in situ molecular profiling, padlock probes that identify specific desired targets to examine biomarkers of clinical relevance in cancer diagnostics were designed and used to create libraries of rolling circle amplification products. We characterize the OPENchip in terms of its capture efficiency and capture purity, and validate the probe design using different cell lines. By integrating the obtained results, molecular analyses of CTCs from metastatic breast cancer (HER2 (ERBB2) gene expression and PIK3CA mutations) and metastatic pancreatic cancer (KRAS gene mutations) patients were demonstrated without any off-chip processes. The results substantiate the potential implementation of early molecular detection of cancer through sequencing-free liquid biopsy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available